KR102945599B1 - 암 치료를 위한 ch5126766과 조합된 vs-6063 - Google Patents

암 치료를 위한 ch5126766과 조합된 vs-6063

Info

Publication number
KR102945599B1
KR102945599B1 KR1020227012129A KR20227012129A KR102945599B1 KR 102945599 B1 KR102945599 B1 KR 102945599B1 KR 1020227012129 A KR1020227012129 A KR 1020227012129A KR 20227012129 A KR20227012129 A KR 20227012129A KR 102945599 B1 KR102945599 B1 KR 102945599B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227012129A
Other languages
English (en)
Korean (ko)
Other versions
KR20220078606A (ko
Inventor
우다이 바네르지
Original Assignee
디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 filed Critical 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀
Publication of KR20220078606A publication Critical patent/KR20220078606A/ko
Application granted granted Critical
Publication of KR102945599B1 publication Critical patent/KR102945599B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227012129A 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063 Active KR102945599B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/074565 WO2021047783A1 (en) 2019-09-13 2019-09-13 Vs-6063 in combination with ch5126766 for the treatment of cancer
EPPCT/EP2019/074565 2019-09-13
PCT/EP2020/056642 WO2021047798A1 (en) 2019-09-13 2020-03-12 Vs-6063 in combination with ch5126766 for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267009252A Division KR20260046532A (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063

Publications (2)

Publication Number Publication Date
KR20220078606A KR20220078606A (ko) 2022-06-10
KR102945599B1 true KR102945599B1 (ko) 2026-03-30

Family

ID=67988988

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012129A Active KR102945599B1 (ko) 2019-09-13 2020-03-12 암 치료를 위한 ch5126766과 조합된 vs-6063

Country Status (11)

Country Link
US (4) US11517573B2 (https=)
EP (1) EP4028010B1 (https=)
JP (3) JP2022547358A (https=)
KR (1) KR102945599B1 (https=)
CN (2) CN114630667B (https=)
AU (1) AU2020344829A1 (https=)
BR (1) BR112022004699A2 (https=)
CA (1) CA3152805A1 (https=)
MX (1) MX2022003063A (https=)
TW (1) TWI857024B (https=)
WO (3) WO2021047783A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
MX2022009612A (es) 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.
AU2021307410A1 (en) * 2020-07-13 2023-02-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
EP4376828A4 (en) * 2021-07-27 2025-06-18 Verastem, Inc. COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
IL312248A (en) * 2021-10-28 2024-06-01 Verastem Inc Combined treatment for abnormal cell proliferation
IL312469A (en) * 2021-11-02 2024-06-01 Verastem Inc Methods of treating abnormal cell growth
TW202329967A (zh) * 2022-01-21 2023-08-01 大陸商應世生物科技（南京）有限公司 治療腫瘤的藥物組合及用途
EP4469086A4 (en) * 2022-01-25 2026-01-21 Verastem Inc POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN114917232A (zh) * 2022-06-27 2022-08-19 厦门骨本生物科技有限公司 Ch5126766在制备缓解或治疗动物骨关节炎的药物中的应用
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物
TW202517624A (zh) * 2023-07-03 2025-05-01 美商醫療免疫工程公司 Mek免疫腫瘤抑制劑醫藥組合物
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150190346A1 (en) 2014-01-09 2015-07-09 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
WO2017004192A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9920908D0 (en) 1999-09-03 1999-11-10 Indena Spa Chalcone coumarins
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
KR101489045B1 (ko) 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AR084216A1 (es) 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
US9133174B2 (en) 2011-09-05 2015-09-15 Chugai Seiyaku Kabushiki Kaisha Method for producing coumarin derivative
WO2013170066A1 (en) 2012-05-09 2013-11-14 H. Lee Moffitt Cancer Center & Research Institute, Inc. Peptides for the treatment of cancer
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
KR20150067323A (ko) 2012-10-12 2015-06-17 글락소스미스클라인 엘엘씨 조합물
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
CA3074690A1 (en) * 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
RU2760006C1 (ru) 2017-11-16 2021-11-22 Дзе Инститьют оф Кансер Рисерч: Ройал Кансер Хоспитал Производное кумарина для лечения или профилактики расстройства пролиферации клеток
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150190346A1 (en) 2014-01-09 2015-07-09 Verastem, Inc. Compositions and methods for treatment of abnormal cell growth
WO2017004192A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use

Also Published As

Publication number Publication date
US11517573B2 (en) 2022-12-06
CA3152805A1 (en) 2021-03-18
JP2025072587A (ja) 2025-05-09
US20220031698A1 (en) 2022-02-03
TW202114677A (zh) 2021-04-16
JP2022172480A (ja) 2022-11-17
BR112022004699A2 (pt) 2022-06-14
TWI857024B (zh) 2024-10-01
CN114630667A (zh) 2022-06-14
AU2020344829A1 (en) 2022-03-03
JP7634351B2 (ja) 2025-02-21
MX2022003063A (es) 2022-06-14
US20240197731A1 (en) 2024-06-20
WO2021047798A1 (en) 2021-03-18
WO2021048339A1 (en) 2021-03-18
KR20220078606A (ko) 2022-06-10
US12280050B2 (en) 2025-04-22
JP2022547358A (ja) 2022-11-14
EP4028010A1 (en) 2022-07-20
WO2021047783A1 (en) 2021-03-18
EP4028010B1 (en) 2026-04-08
US20230277535A1 (en) 2023-09-07
CN114630667B (zh) 2025-05-13
US20260034128A1 (en) 2026-02-05
CN120678780A (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
KR102945599B1 (ko) 암 치료를 위한 ch5126766과 조합된 vs-6063
JP2022172480A5 (https=)
US20230330088A1 (en) Combination therapy for treating abnormal cell growth
US20230321097A1 (en) Methods and compositions for treating abnormal cell growth
KR20230011908A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
KR20240041978A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
KR20230011277A (ko) 비정상적 세포 성장의 치료 방법
KR20260046532A (ko) 암 치료를 위한 ch5126766과 조합된 vs-6063
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
BR112017028519B1 (pt) Uso de defactinibe na preparação de um medicamento para tratamento de câncer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)